Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 14/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 7/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 1/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 1/20 | 1.00 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25096205 | 1.00 | PTK6 (1.00) | PTK6ERBB2AURKAEGFRSRC | |
| SCHEMBL684772 | 0.83 | PTK6 (0.71) | PTK6ERBB2AURKAEGFRSRC | |
| SCHEMBL675375 | 0.81 | PTK6 (0.79) | PTK6ERBB2AURKAEGFRSRC | |
| SCHEMBL675486 | 0.80 | PTK6 (1.00) | PTK6ERBB2AURKAEGFRSRC | |
| SCHEMBL4882303 | 0.76 | EGFR (0.69) | PTK6ERBB2AURKAEGFRSRC | |
| SCHEMBL16024047 | 0.76 | ERBB2 (0.61) | PTK6ERBB2AURKAEGFRSRC | |
| SCHEMBL858313 | 0.74 | TTBK1 (0.63) | PTK6ERBB2AURKAEGFRSRC | |
| SCHEMBL13461148 | 0.72 | ERBB2 (0.70) | PTK6ERBB2AURKAEGFRSRC | |
| SCHEMBL6522191 | 0.72 | PTK6 (0.77) | PTK6ERBB2AURKAEGFRSRC | |
| SCHEMBL6521467 | 0.72 | AURKA (0.74) | PTK6ERBB2AURKAEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119889425-A | PTK6/hnRNPH1/NBR 1-based computer-aided drug screening method, system and device | 徐州医科大学附属医院 | 2025-04-25 | — | — | CN | claimed |
| US-20240358678-A1 | METHODS AND COMPOSITIONS FOR ENHANCING CHEMOTHERAPEUTIC DRUG UPTAKE INTO BRAIN TUMORS | BROWN UNIVERSITY | 2024-10-31 | — | — | US | claimed |
| WO-2026102161-A1 | METHODS OF TREATING OVARIAN AND PANCREATIC CANCER | CONCARLO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4712963-A2 | SMALL MOLECULE INHIBITORS OF P27 | Concarlo Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| CN-119889425-A | PTK6/hnRNPH1/NBR 1-based computer-aided drug screening method, system and device | 徐州医科大学附属医院 | 2025-04-25 | — | — | CN | disclosed |
| CN-113329749-B | Combination therapy for the treatment of uveal melanoma | 伊利诺伊大学董事会 | 2025-02-11 | — | — | CN | disclosed |
| EP-3852744-B1 | COMBINATION THERAPY FOR THE TREATMENT OF UVEAL MELANOMA | UNIV ILLINOIS (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024238709-A2 | SMALL MOLECULE INHIBITORS OF P27 | CONCARLO THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240358678-A1 | METHODS AND COMPOSITIONS FOR ENHANCING CHEMOTHERAPEUTIC DRUG UPTAKE INTO BRAIN TUMORS | BROWN UNIVERSITY | 2024-10-31 | — | — | US | disclosed |
| US-12090153-B2 | Combination therapy for the treatment of uveal melanoma | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-09-17 | — | — | US | disclosed |
| US-11384150-B2 | Antibody-drug conjugates and uses thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358678-A1 | METHODS AND COMPOSITIONS FOR ENHANCING CHEMOTHERAPEUTIC DRUG UPTAKE INTO BRAIN TUMORS | SLC19A1, SLC5A7, FABP7 | PTK6 3533/4885ERBB2 807/4885AURKA 1446/4885 |
| US-11384150-B2 | Antibody-drug conjugates and uses thereof | EGFR, ERBB2, ERBB3 | PTK6 24/4885ERBB2 2/4885AURKA 97/4885 |
| US-12090153-B2 | Combination therapy for the treatment of uveal melanoma | GNAQ, GNA11, GNB1 | PTK6 1388/4885ERBB2 1648/4885AURKA 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.